

THURSDAY  
5<sup>th</sup> JUNE  
2025

afpbn

ASSOCIATION FRANÇAISE  
DE PSYCHIATRIE BIOLOGIQUE  
NEUROPSYCHOPHARMACOLOGIE

afpbn

section  
médecine  
psychédélique

# PSYCHEDELIC MEDICINE: SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

## Organizing Committee :

Dr. Lucie Berkovitch (Paris)

Dr. Hugo Bottemanne (Paris)

Prof. Luc Mallet (Paris)

Dr. Bruno Roméo (Villejuif)

All presentations will be delivered in English only, with no live translation available.  
Please note that no replay is currently scheduled.

**ICM - Institut du Cerveau**

Hôpital Pitié-Salpêtrière  
47 bd de l'Hôpital, 75013 Paris

Soutenu  
par le



**GOUVERNEMENT**

Liberté  
Égalité  
Fraternité

**MILDECA**

Mission interministérielle  
de lutte contre les drogues  
et les conduites addictives

# PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

8:45 AM: Welcome

9:00 AM: Introduction - Bureau of the Psychedelic Medicine Section

09:15–10:00 AM: Pharmacology of psychedelics: similarities and differences - Matthias Liechti, Basel University

*Chair : Carine Becamel, Montpellier*

10:00–10:45 AM: Psychedelic therapies - How do they seem to differ from existing treatments in mental health?

David Erritzoe, Imperial College of London

*Chair : Anne Claret-Tournier, Paris*

10:45 –11:00 AM: Coffee Break

11:00 –11:45 AM: Mechanisms of psychedelics in the treatment of alcohol dependence - Mickael Naassila, University of Picardy

*Chair : Alain Gardier, Orsay*

11:45–12:30 AM: Are the neurobiological properties of psychedelics predictive of therapeutic effects in addiction?

Christian Lüscher, University of Geneva

*Chair : Marc Gielen, Créteil*

12:30–1:30 PM: Lunch Break (lunchbox distribution)

# PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the AFPBN

**1:30 –2:00 PM:** Processes and challenges in setting up a psilocybin study in France: example of the first French study (PAD)

Amandine Luquiens, CHU Nîmes

*Chair : Jérôme Jeanblanc, Amiens*

**2:00–2:45 PM:** Global brain effects of psychedelics and therapeutic implications

Katrin Preller, University Hospital for Psychiatry, Zurich

*Chair : Baptiste Fauvel, Paris*

**2:45–3:30 PM:** LSD in the treatment of mood and anxiety disorders

Frederike Holze, Basel University

*Chair : Alexandre Alt, Geneva*

**3:30–3:45 PM:** Coffee Break

**3:45 –4:30 PM:** Psilocybin as a catalyst for psychotherapy? Insights from the German EPIsoDE Trial

Lea Mertens, Central Institute of Mental Health, Heidelberg

*Chair : Laetitia Vanderijst, Bruxelles*

**4:30–5:15 PM:** Prospects on the use of psychedelic treatments as antidepressant therapy

Guy Goodwin, COMPASS Pathways, London

*Chair : Michael Koslowski, Berlin*

**5:15–5:30 PM:** Closing Remarks, Bureau of the Psychedelic Medicine Section

# PSYCHEDELIC MEDICINE : SCIENTIFIC PERSPECTIVE

1st National Symposium of the Psychedelic Medicine Section of the Afpbn

afpbn  
section  
médecine  
psychédélique



SCANNEZ LE QR CODE POUR VOUS INSCRIRE !

AGENCE PCO : COM'TO EVIDENCE

[www.comtoevidence.com](http://www.comtoevidence.com)



COM'TO  
EVIDENCE

CONTACT :

Mathias BRACCHETTI-GRANET

Email : [contact@comtoevidence.com](mailto:contact@comtoevidence.com)

Tél. : 33 (0)9 81 25 85 82